- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01058876
Comparison of Low Yield Cigarettes in African Americans vs. Whites (6162-AAPK2)
Nicotine Regulation/Response to Low Yield Cigarettes in African-Americans vs. Whites
The investigators' general hypothesis is that African-Americans (AAs) smoke more for positive reinforcement from nicotine with a "peak-seeking" pattern of smoking (smoking individual cigarettes more intensively with greater intake of nicotine and tobacco smoke toxins), while whites smoke more for negative reinforcement with a "trough-maintaining" pattern (avoiding withdrawal by maintaining more consistent nicotine levels throughout the day by means of a more regular smoking pattern). We, the investigators, believe that these patterns are linked to identifiable racial differences in nicotine pharmacology.
For this study we hypothesize that if AAs behave more like nicotine "peak-seeker" while whites behave more like nicotine "trough-maintainers", that AAs will respond to switching from regular to low nicotine yield commercial cigarettes by smoking each cigarette relatively more intensively with a relatively smaller increase in daily cigarette consumption (cigarettes per day or CPD) as compared to whites.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Several lines of evidence indicate that AAs are more highly addicted to cigarette smoking than are whites. AAs are more likely to smoke their first cigarette within 10 minutes of awakening, an indicator of the severity of the dependence. They are more likely to want to quit smoking and are more likely to try to quit (attempts lasting at least 24 hours, but are significantly less likely than whites to be successful abstainers at one year. The quit ratio (former smokers/ever smokers) was recently reported to be 37.3% in AAs compared to 51% for whites (2).
NICOTINE REGULATION IN AAS AND WHITES: In general smokers regulate (titrate) their smoking to take in about the same amount of nicotine from day to day. This behavior is well demonstrated in studies of smokers smoking commercial cigarettes of differing yields, showing that smokers take in similar amounts of nicotine from high- and low-yield cigarettes. NCI MONOGRAPH 13 summarized the data on nicotine and low yield cigarettes and concluded that low yield cigarettes presented the same health risks as high yield cigarettes (12). However, most or all of the research on nicotine titration appears to have been done primarily in white smokers.
We believe that nicotine titration patterns will differ in AAs compared to whites, based on the hypothesis that AAs smoke more for the positive reinforcing effects of individual cigarettes, while whites smoke more to maintain a consistent level of nicotine. We predict that the response to switching from regular to low yield cigarettes in AAs will differ in that they will try to take in more nicotine per cigarette by smoking more intensively, but will be less likely to try to regulate their total daily intake of nicotine compared to whites.
Melanin: A recent study (14) showed that levels of facultative melanin (includes both genetically and exposure influenced melanin) in the skin are significantly and positively related to cigarettes per day, the Fagerstrom score, and cotinine levels. By measuring melanin levels in our own study subjects, we will be able to determine if there is a relationship between melanin levels and nicotine pharmacokinetics.
This is a non-randomized, non-blinded, two treatment arm crossover study with an oral nicotine and cotinine pharmacokinetic study. Cigarettes will be supplied for both treatment arms and subjects will smoke ad libitum. During the first arm, the subject will smoke their "usual" cigarettes and also undergo an oral pharmacokinetics protocol. During the second arm, subjects will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their "usual" brand.
Blood and urine samples will be collected throughout the study and analyzed by our usual methods.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- University of California, San Francisco, San Francisco General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sex: male or female (balanced numbers)
- Age: 18- 65
- Race/ethnicity: African-American or White (based on two parents who self- identify as AA or White, respectively)
- Smoking Status: Current daily smoker of at least 10 cigarettes per day; either menthol or non-menthol. Screening saliva cotinine level of > 100 ng/ml.
Healthy by history and assessment of vital signs.
Exclusion Criteria:
- Evidence of cardiac disease by history
- Recent or current history of asthma or severe allergic rhinitis
- Hypertension (blood pressure [BP] >140/90 at screening after 5 min rest)
- Serious medical or psychiatric condition or other condition requiring regular medication use
- Lack of access to a refrigerator to store saliva specimens collected at home
- Morbid obesity (body mass index [BMI]>35)
- Current illicit drug use by history and tox screen (however subjects using marijuana may be included if they are not daily users and will agree to abstain from the time of screening until the end of the study)
- Pregnancy or breastfeeding
- Significant history of fainting, "bad veins", discomfort with blood draws
- Current or recent alcohol or drug abuse
- Inability to speak English/read forms or aversion to filling out forms
- Multiple or unexplained "no shows" for screening/study visits or other noncompliance with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Usual Cigarette
African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
|
used as a marker for pharmacokinetic studies
|
Experimental: Low-yield Cigarette
African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their "usual" brand.
|
used as a marker for pharmacokinetic studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nicotine clearance
Time Frame: 14 days
|
14 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-00158
- NIDA DA002277 (NIDA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cigarette Smoking
-
Maastricht University Medical CenterCompletedCigarette Smoking | Cigarette Smoking Toxicity | Smoking BehaviorNetherlands
-
Duke UniversityGeorgetown University; University of MichiganWithdrawnSmoking | Cigarette Smoking | E-cigarette Use
-
Assistance Publique - Hôpitaux de ParisUnknownSmoking Cessation | Smoking, Cigarette | Electronic CigaretteFrance
-
Yale UniversityNational Cancer Institute (NCI)RecruitingSmoking Cessation | Cigarette Smoking | E-Cigarette UseUnited States
-
Medical University of South CarolinaAmerican Cancer Society, Inc.RecruitingSmoking Cessation | Electronic Cigarette Use | Cigarette SmokingUnited States
-
University of St AndrewsNational Health Service, United KingdomUnknownSmoking | Cigarette Smoking | Smoking, Tobacco
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
-
BIDI VaporCompletedCigarette Smoking | E-cigarette UsePoland
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
Andrew StrasserNational Institute on Drug Abuse (NIDA); Food and Drug Administration (FDA); Rutgers...RecruitingCigarette Smoking | Smoking BehaviorsUnited States
Clinical Trials on Deuterated nicotine and cotinine
-
University of California, San FranciscoCompletedCigarette SmokingUnited States
-
National Institute on Drug Abuse (NIDA)University of MinnesotaCompleted
-
National Institute on Drug Abuse (NIDA)University of MinnesotaCompleted
-
National Institute on Drug Abuse (NIDA)University of MinnesotaCompleted
-
University of JordanCompleted
-
University of OxfordWellcome Trust; St George's, University of LondonCompleted
-
University of MinnesotaActive, not recruiting
-
Masonic Cancer Center, University of MinnesotaCompleted
-
University of VermontNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedInsulin Resistance | Adipocyte DifferentiationUnited States
-
Retrotope, Inc.Active, not recruitingInfantile Neuroaxonal DystrophyUnited States